ClinicalTrials.gg
CompletedNCT00627679UDB P101Updated Jan 9, 2014Results posted

Safety and Blood Level Study of Unit Dose Budesonide

A Phase 1 interventional study of Budesonide Inhalation Suspension and MAP0010 low dose in Asthma, sponsored by Allergan. Completed at 1 site in Australia. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-01-09.

Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
99th of 108
16 · median 124
Started
2005
with 5 others
Phase 1
10 of 110
none open now
Registered
38th of 110
by date
Lead sponsor
5 of 110
Allergan

Among the 110 studies testing budesonide in Asthma, this one is the 99th largest by enrollment of the 108 interventional ones that give a count, is one of 6 that started in 2005, is one of 10 in phase 1, and was the 38th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy volunteers.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Pediatric asthma
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers, aged 18-50 years
  • less than 30 kg/m2
  • Non smoker (currently and \<10 pack years total if ex-smoker)

Exclusion criteria

Exclusion Criteria:

  • Any use of in previous 4 weeks
  • Pregnancy/lactation
  • Significant blood donation (or testing) in previous 8 weeks
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Treatment sequence: A, B, D, C

    Treatment visits were separated by a 48-72 hour washout period. Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 2; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 3; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 4; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 5

    Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose

  • Experimental
    Treatment sequence: B, C, A, D

    Treatment visits were separated by a 48-72 hour washout period. Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 2; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 3; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 4; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 5

    Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose

  • Experimental
    Treatment sequence: C, D, B, A

    Treatment visits were separated by a 48-72 hour washout period. Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 2; Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 3; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 4; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 5

    Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose

  • Experimental
    Treatment sequence: D, A, C, B

    Treatment visits were separated by a 48-72 hour washout period. Treatment D = a single dose of MAP0010 high dose delivered by nebulization at Visit 2; Treatment A = a single dose of Budesonide inhalation suspension (Pulmicort Respules®) delivered by nebulization at Visit 3; Treatment C = a single dose of MAP0010 intermediate dose delivered by nebulization at Visit 4; Treatment B = a single dose of MAP0010 low dose delivered by nebulization at Visit 5

    Drug: Budesonide Inhalation Suspension · Drug: MAP0010 low dose · Drug: MAP0010 intermediate dose · Drug: MAP0010 high dose

Interventions

  • Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

    Also known as: Pulmicort Respules®

  • Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

  • Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

  • Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.

06

What researchers measure

Primary outcomes

  1. Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010

    The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).

    Time frame: 8 hours

  2. Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010

    Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).

    Time frame: 8 hours

  3. AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010

    The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg\*min/ml).

    Time frame: 8 hours

  4. AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010

    The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).

    Time frame: 8 hours

  5. Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010

    Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).

    Time frame: 8 hours

07

Results

Posted Oct 23, 2013

Participant flow

Participant flow — Overall Study
MilestoneTreatment A, B, D, CTreatment B, C, A, DTreatment C, D, B, ATreatment D, A, C, B
Started4444
Completed4444
Not completed0000

Outcome measures

PrimaryCmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010

The maximum concentration (Cmax) is the highest concentration of a drug measured in the plasma. Plasma is the clear portion of the blood. The Cmax of Budesonide is reported in picograms per milliliter (pg/ml).

Time frame:
8 hours
Reported as:
Mean · pg/mL
Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010
pg/mLTreatment ATreatment BTreatment CTreatment D
Cmax of of Budesonide After Administration of Pulmicort and Three Dose Levels of MAP0010303.5 ± 177.4106.2 ± 63.47239.9 ± 140.1434.5 ± 246.9
PrimaryTmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010

Tmax is the time to maximum concentration of a drug in the plasma. The Tmax of budesonide is reported in minutes (min).

Time frame:
8 hours
Reported as:
Mean · min
Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010
minTreatment ATreatment BTreatment CTreatment D
Tmax of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP00109.063 ± 7.1224.467 ± 3.2703.125 ± 1.5003.688 ± 1.448
PrimaryAUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010

The AUC(0-8) is the area under the plot of plasma concentration of drug against time after drug administration. Budesonide AUC(0-8) is reported in picograms times minutes per milliliter (pg\*min/ml).

Time frame:
8 hours
Reported as:
Mean · pg*min/mL
AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP0010
pg*min/mLTreatment ATreatment BTreatment CTreatment D
AUC(0-8) of Budesonide After Administration of Pulmicort Respules® and Three Doses of MAP001029040 ± 93163978 ± 19748626 ± 418422130 ± 9675
PrimaryAUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010

The AUC(0-inf) is the area under the plot of plasma concentration of drug against time to infinity (inf) after drug administration. Budesonide AUC(0-inf) is reported in picograms times minutes per milliliter (pg\*min/ml).

Time frame:
8 hours
Reported as:
Mean · pg*min/mL
AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010
pg*min/mLTreatment ATreatment BTreatment CTreatment D
AUC(0-inf) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP001031480 ± 106904391 ± 14237842 ± 364725290 ± 11750
PrimaryHalf-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010

Half-life (t1/2) is the time for the drug to decrease to half of its maximum concentration. Budesonide t1/2 is reported in minutes (min).

Time frame:
8 hours
Reported as:
Mean · min
Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010
minTreatment ATreatment BTreatment CTreatment D
Half-life (t1/2) of Budesonide After Administration of Pulmicort Respules® and Three Dose Levels of MAP0010145.4 ± 40.8473.02 ± 33.4378.35 ± 27.08140.0 ± 54.19

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A—0/16 (0%)4/16 (25%)
Treatment B—0/16 (0%)4/16 (25%)
Treatment C—0/16 (0%)3/16 (18.8%)
Treatment D—0/16 (0%)3/16 (18.8%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment D
anemiaBlood and lymphatic system disorders0/160/162/161/16
dysmenorrhoeaReproductive system and breast disorders2/160/160/160/16
thrombophlebitisVascular disorders0/160/161/160/16
hematomaVascular disorders0/160/160/161/16
epitaxisRespiratory, thoracic and mediastinal disorders0/160/160/161/16
pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders0/161/160/160/16
headacheNervous system disorders0/161/160/160/16
herpes simplexInfections and infestations0/161/160/160/16
vaginal candidiasisInfections and infestations0/161/160/160/16
hordeolumInfections and infestations1/160/160/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Patients
Mean23.3 ± 4.3
Sex: Female, Male
Sex: Female, Male(Participants)All Patients
Female8
Male8
08

Study locations

1 site
  • Q-Pharm Pty Limited
    Brisbane, Queensland QLD 4006, Australia
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Dec 2005 and a completion of May 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2013, 7 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2008
First posted
Mar 3, 2008
Start
Dec 2005
Primary completionActual
Dec 2005
CompletionActual
May 2006
Results first posted
Oct 23, 2013
Last update
Jan 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00627679
Lead sponsor
Allergan
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan, Q-Pharm Pty Limited
Responsible party
Sponsor
First posted
Mar 3, 2008
Start date
Dec 2005
Primary completion
Dec 2005
Completion
May 2006
Results posted
Oct 23, 2013
Last update
Jan 9, 2014

Study contacts

Joanne Marjason, MBBS
principal investigator · Q-Pharm Pty Limited

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion